Table of Contents
- Executive Summary
- Strategic Considerations
- Trends and Their Implications for Stakeholders
- Evolving Biologics Market
- Alzheimer' s Disease and Anti-Amyloid Antibodies
- Elan/Wyeth' s AAB-001 (Bapineuzumab)
- MAbs in Early-Stage Clinical Development for Alzheimer' s Disease
- Anti-Integrin Antibodies
- Biogen Idec/Elan' s Tysabri (Natalizumab)
- Anti-Integrin Antibodies in Early-Stage Clinical Development
- Biogen Idec/PDL BioPharma' s M-200 (Volociximab)
- Johnson & Johnson/Centocor/Medarex' s CNTO-95
- Millennium' s MLN-0002
- Selective T-Cell Co-Stimulation Antagonists
- Superagonist Debacle
- Bristol-Myers Squibb' s Orencia (Abatacept)
- Three Phase III Contenders
- Bristol-Myers Squibb' s LEA29Y (Belatacept)
- Medarex/Bristol-Myers Squibb' s MDX-010 (Ipilimumab)
- Pfi zer' s CP-675,206 (Tremelimumab)
- Complement and Complement Receptor Antibodies
- HIV Antibody Therapies
- Blocking Immune Cell Migration to Infl ammation Sites
- Cytotoxicity-Enhanced CCR4 Antibody
- B-Cell-Targeted Therapies: Anti-CD20 Antibodies
- Biogen Idec/Genentech/Roche/Chugai/Zenyaku' s Rituxan/MabThera (Rituximab)
- Anti-CD20 Antibodies in Clinical Development
- Biogen Idec/Genentech/Roche' s R-1594/PRO-70769 (Ocrelizumab)
- GlaxoSmithKline/Genmab' s HuMax-CD20 (Ofatumumab)
- Immunomedics' IMMU-106 (Veltuzumab)
- Next-Generation Engineered Antibodies
- Radioimmunotherapy
- T-Cell-Targeted Therapies
- Anti-CD3 Antibodies
- Agents in Development for Recent-Onset Type 1 Diabetes
- Agents in Development for Infl ammatory Bowel Diseases
- CD4-Targeting Antibodies
- Novel Interleukin-6 Receptor Antagonist Class
- Tumor Necrosis Factor-Alpha Inhibitors
- EGFR-Targeted Therapies
- Bristol-Myers Squibb/ImClone Systems /Merck Serono' s Erbitux (Cetuximab)
- Amgen' s Vectibix (Panitumumab)
- EGFR Antagonists in Clinical Development
- Oncoscience/YM Bioscience/Daiichi Sankyo' s TheraCIM h-R3/Theraloc
(Nimotuzumab)
- Genmab' s HuMax-EGFR (Zalutumumab)
- Merck Serono/Takeda' s EMD-72000 (Matuzumab)
- Bristol-Myers Squibb/ImClone Systems' IMC-11F8
- Anti-VEGF Angiogenesis Inhibitors
- Genentech/Roche/Chugai' s Bevacizumab (Avastin)
- Drug Resistance and Combination Therapies
- Genentech/Novartis' s Lucentis (Ranibizumab)
- ThromboGenics/BioInvent' s TB-403
- Four Developing Trends
- Trend 1
- Trend 2
- Trend 3
- Trend 4
Tables:
- 1. Alzheimer' s Disease and Anti-Amyloid Antibodies
- 2. Anti-Integrin Antibodies
- 3. Selective T-Cell Co-Stimulation Antagonists
- 4. Select Complement Receptor Antibodies
- 5. Anti-CD20 Antibodies
- 6. Anti-CD3 Antibodies
- 7. Anti-CD4 Antibodies
- 8. Tumor Necrosis Factor Alpha (TNF-α) Antibodies
- 9. Anti-EGFR Antibodies
- 10. Anti-VEGF Angiogenesis Inhibitors
Figures:
- 1. Evolving Pharmaceutical Market Segments Based on Technology, 2000-2012
- 2. Top-Selling Monoclonal Antibodies, 2007
- 3. Amyloid Plaques and Neurofi brillary Tangles in Alzheimer' s Disease
- 4. Mechanisms of T-Cell Co-Stimulation
- 5. The Life Cycle of HIV-1
- 6. EGFR Family
- 7. The Angiogenic Process
- 8. TNF-Alpha Inhibitors, 2006-2016: Market Share
Decision Resources, Inc., Analysts Featured
- Madhuri Borde, Ph.D., analyst, Immune and Infl ammatory Disorders
- Sylvia Eash, Ph.D., analyst, Infectious Disease
- Clair Gricks, Ph.D., analyst, Onkos
- Neil Grubert, M.A., director of pricing and reimbursement, Spectrum,
Pharmacoeconomics, Pricing, and Reimbursement
- Bethany A. Kiernan, Ph.D., analyst, Cognos
- Joanna Kim, M.Ed., analyst, Immune and Infl ammatory Disorders
- Nitasha Manchanda, Ph.D., analyst, Cognos
- Jennifer Moniz Carpenter, M.B.A., program manager, Spectrum, Therapy
Markets and Emerging Technologies
- Mohamed Muhsin, M.Sc., analyst, Onkos
- Alice von Loesecke, Ph.D., senior director, New Products
|
Related Report
|
View Cart
